Alle Publikationen

Filtern Sie das Suchergebnis:

Alle Vortrag Poster Abstract Fullpaper

Ihr Suchergebnis:

(1) Musholt PG., Schöndorf T., Pfützner A., Hohbert C., Kleine I., Fuchs W., Hehenwarter S., Dikta G., Kerschgens B., Forst T.
Combined Pioglitazone and Metformin Treatment Maintains the Beneficial Effect of Short-Term Insulin Infusion in Patients with Type 2 Diabetes
Results from a Pilot Study. J of Diab Science and Technology. Vol 3, Vol 3, Iss 6 (Nov. 2009)
(Fullpaper)

(2) Forst T., Hohberg C., Tarakci E., Forst S., Kann P., Pfützner A.
Reliability of Lightguide Spectrophotometry (O2CR) for the Investigation of Skin Tissue Microvascular Blood Flow and Tissue Oxygen Supply in Diabetic and Nondaibetic Subjects.
J of Diab Science and Technology. Vol 2, 151-155 (Nov. 2008)
(Fullpaper)

(3) Schöndorf T., Karagiannis E., Posseldt RE., Forst T., Pfützner A.
Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type diabetes patients with insufficient glycemic control by metformin alone – results from a post-marketing surveillance trial under daily routine conditions.
Diabetes Technol Ther., 11(6):379-83 (Jun 2009)
(Fullpaper)

(4) Forst T., Hohbert C., Schöndorf T., Borchert M., Forst S., Roth W., Dehos B. Pfützner A.
Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the Plex Pen device.
Diabetes Technol Ther, 11(2): 87-92 (Feb. 2009)
(Fullpaper)

(5) Foucher AL, Hartmann K., Hauptmann M., Wildgrunber R., Safinowski M., Forst T., Pfützner A., Gelfand CA., Nissum M.
Resolution of adiponenctin oligomers in human plasma using free flow electrophoresis.
Arch Physiol Biochem, 115(5):267-8 (Dez. 2009)
(Fullpaper)

(6) Pfützner A., Prause S., Eidens M., Weise A., Forst T.
Pharmgenomics of Metabolic Disease.
Gent The EuroEspes Journal, No. 4, S. 9-16 (Dez. 2009)
(Fullpaper)

(7) Dahmen N., Manderscheid N., Helfrich J., Musholt PB, Forst T, Pfützner A., Engel A.
levated peripheral visfatin levels in narcoleptic patients.
PloS One, 3(8):e2980 (Aug. 2008)
(Fullpaper)

(8) Pfützner A., Harzer O., Mushol PB., Scherer S., Löbig M., Forst T.
Performance of Blood Glucose Measurement Systems Influenced by Interfering Substances.
Diabetes, Stoffwechsel und Herz, Band 18 (5/2009)
(Fullpaper)

(9) Pfützner A., Safinowski M., Forst T.
Problems with the determination of nitrotyrosine in human plasma are not solved in a satisfactory way and conclusions from clinical trials need to be carefully revised.
Clin Chem Labo Med 2010, 48 (1): 145-146 (2010)
(Fullpaper)

(10) Forst T., Pfutzner A., Flacke F., Krasner A., Hohberg C., Tarakci E., Pichotta P. Forst S., Steiner S.
Postprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 Diabetes.
Diabetes Care, Col 33, Number 1 (2010)
(Fullpaper)

(11) Hanefeld M., Schönauer M., Forst T.
Blutzucker-Senkung und kardiovaskulärer Vorteil: Was wissen wir heute?
DMW 135, Jahrgang; 7; 19.2.2010, Sonderdruck (2010)
(Fullpaper)

(12) Forst T., Larbig M., Hohberg C., Forst S., Diessel S., Borchert M., Roth W., Pfützner A.
Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postptrandial ?-cell protection in individuals with type 2 diabetes.
Doabetes. Pbesoty amd ;etabpöos,, 12: 437-441, 2010 (2010)
(Fullpaper)

(13) Forst T., & Pfützner A
Grundlagen des Diabetes für Neurologen.
DNP Der Neurologe und Psychiater., 5/10; 67-72 (2010)
(Fullpaper)

(14) Forst T., Weber M. M., Hohberg C., Pfützner A.
Pharmakologische Aspekte in der Therapie der diabetischen Polyneuropathie.
Diabetes Stoffw Herz 2010, 10:261-273 (2010)
(Fullpaper)

(15) Forst T., Hanefeld M., Pfützner A
Verordnungsausschluss der Glitazone: Arme deutscher Typ 2-Diabetiker.
Diabete Stoffw Herz, Band 19, 4/2010, 292-295 (2010)
(Fullpaper)

(16) Forst T., Hohberg H., Pfützner A.
Effects of Disturbed Insulin Activity in Metabolic Syndrome and in Type 2 Diabetic Patients.
Horm Metab Res, 41:123-131 (2009)
(Fullpaper)

(17) Safinowski M., Wilhem B., Reimer T., Weise A., Thomé Nicole, Hänel H., Forst T., Pfützner A.
Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests.
Clin Chem Lab, 47(4):483-488 (2009)
(Fullpaper)

(18) Storz H, Klilian J M, Ehrhardt F, Gomez I, Shriley S, Gessner P, Zimmermann G, Weyand E, Sukhorukov V L, Forst T, Weber M M, Zimmermann H, Kulicke W M, Zimmermann U
Physiochemical features of ultra high viscosity alginates
Carbohydrate Research 344, 985-995 (2009)
(Fullpaper)

(19) Pfützner A., Karagiannis E., Löbig M., Armbruster F.P., Hanefeld M., Forst T.
Differences in the Results and Interpretation of Oxidized LDL Cholesterol by Two ELISA Assays – An Evaluation with Samples from the PIOstat Study.
Clin Lab , 55: 275-281 (2009)
(Fullpaper)

(20) Forst T., Hach T., Kunt T., Weber M.M., Pfützner A.
Molecular Effects of C-Peptide in Microvascular Blood Flow Regulation.
Journal of the Society for Biomedical Diabetes Research, Vo. 5, No. 3, Fall 2009, 159-167 (2009)
(Fullpaper)

(21) Prause S., Eidens E., Weise A., Weber M.M., Forst T., Pfützner A.
Development of a high-throughput method for screening the dopamine D2 (DRD2) receptor gene polymorphismus based on the LightCycler system.
Clin Lab, 55 (9-19);353-8 (2009)
(Fullpaper)

(22) Eidens M., Weise A., Prause S., Dahmen N., Wunsch A., Weber M.M., Forst T., Pfützner A.
Development and validation of a high-throughput screening method for two polymorphisms in the serotonin transporter gene.
Mol Diagn Ther., 13(1): 25-9 (2009)
(Fullpaper)

(23) Pfützner A., Weber M., Forst T.
A Biomarker Concept for Assessment of Insulin Resistance, ß-Cell Function and Chronic Systemic Inflammation in Type 2 Diabetes Mellitus.
Clin Lab, 54: 485-490 (2008)
(Fullpaper)

(24) Forst T., Hohberg C., Tarakci E., Forst S., Kann P., Pfützner A.
Reliability of Lightguide Spectrophotometry (O2CR) for the Investigation of Skin Tissue Microvascular Blood Flow and Tissue Oxygen Supply in Diabetic and Nondaibetic Subjects.
J of Diab Science and Technology. Vol 2,, Issue 6 November 2008. 151-155 (2008)
(Fullpaper)

(25) dsds
Postrandialer Stoffwechsel, endotheliale Dysfunktion und Arteriosklerose.
Diabetes, Stoffwechsel und Herz , 6/2008, 467-472 (2008)
(Fullpaper)

(26) Forst T., Wilhelm B., Pfützner A., Fuchs W., Lehmann U., Schaper F., Weber M., Müller, J., Konrad T., Hanefeld M.
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Diabetes and Vascular Disease Research Vol 5, 4 November 2008, 298-303 (2008)
(Fullpaper)

(27) Pfützner A., Weber M. M., Forst T.
Biomarkers for Assessing Beta-Cell Function and Insulin Resistance in Type 2 Diabetes.
Diabetes, Stoffwechsel und Herz. Suppl. 1/2008, 37-41 (2008)
(Fullpaper)

(28) Hohberg C., Diessel S.P., Afzal Dekordi L., Pfützner A., Forst T.
-
Diabetes, Stoffwechsel und Herz., Supppl 1/2008, 43-47 (2008)
(Fullpaper)

(29) Pfützner A, Forst T
Glitazone haben einen Zusatznutzen – aber dann doch eigentlich wieder nicht?
Diabetes, Stoffwechsel und Herz, 5/2008 407-410 (2008)
(Fullpaper)

(30) Schöndorf T., Forst T., Hohberg C., Pahler S., Link C., Roth W., Pfützner A.
The IRIS III - Study: Pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight.
Diab. Of Science and Technology Volume 2, Issue 2 (2008)
(Fullpaper)

(31) Forst T., Kunt T, Wilhelm B., Weber M. M., Pfützner A.
Role of C-Peptide in the Regulation of Microvascular Blood Flow.
Experimental Diabetes Research., Art. ID 176245, 8 pages (2008)
(Fullpaper)

(32) Hach T., Forst T., Kunt T., Ekberg K., Pfützner A., Warren W.
C-Peptide and ist C-Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients.
Experimental Diabetes Reearch, Volume 2008, Art. ID 730594, 6 pages (2008)
(Fullpaper)

(33) Wilhelm B., Kann P., Pfützner A.
Influence of C-Peptide on Glucose Utilisation.
Experimental Diabetes Research Col., Art. ID 769483, 3 pages (2008)
(Fullpaper)

(34) Siebenhaar R., Weise A., Safinowski M., Reisinger K., Musholt P. B., Reimer T., Forst T., Pfützner A.
Clinical and Laboratory Evaluation of a New Specific ELISA for Intact Proinsulin.
Stoffwechsel und Herz 2, 275-281 (2008)
(Fullpaper)

(35) Hohberg C., Forst T., Larbig M., Safinowski M., Diessel S., Hehenwarter S., Weber M. M., Schöndorf T., Pfützner A.
Effect of Insulin Glulisine on Microvascular Blood Flow and Endothelial Function in the Postprandial State.
Diabetes Care 31 (5), 1021-1025 (2008)
(Fullpaper)

(36) Karagiannis E., Pfützner A., Forst, T., Lübben G., Roth W., Grabellus M, Flannery M., Schöndorf T
The IRIS V Study: Pioglitazone Improves Systemic Chronic Inflammation in Patients with Type 2 Diabetes Under Daily Routine Conditions.
vkjdskvjmsxjv, 206-212 (2008)
(Fullpaper)

(37) Forst T., Hohberg C., Weber M.M., Pfützner A.
Schokolade bei Diabetes mellitus – ungeeignetes Lebensmittel oder süßes Lebenselexier?
Diabetes, Stoffwechsel und Herz (1), 41-51 (2008)
(Fullpaper)

(38) Weise A., Scherzer J., Grenningloh M., Schöndorf T., Hauth W., Lipfert B., Forst T., Pfützner A.
Genauigkeit des Blutzuckermessgerätes Stada Glucocheck im Vergleich zu anderen Geräten.
Diabetes, Stoffwechsel und Herz (1), 25-31 (2008)
(Fullpaper)

(39) Forst T., Karagiannis E., Lübben G., Hohberg C., Schöndorf T., Dikta G., Drexler M., Morcos M., Dänschel W., Borchert M., Pfützner A.
Pleiotrophic and Anti-inflammatory Effects of Pioglitazone precede the Metabolic Activity in Type 2 Diabetic Patients with Coronary Artery Disease
Atherosclerosis, doi:10.1016 (2007)
(Fullpaper)

(40) Forst T., Pfützner A.
Kurzwirksame Insulinanaloga bei Typ-1-Diabetes ohne Zusatznutzen
Stoffwechsel und Herz (6), 459-467 (2007)
(Fullpaper)

(41) fützner A., Hanefeld M., Lübben G., Weber M.M., Karagiannis E., Köhler C., Hohberg C., Forst T.
Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk – Results from the PIOSTAT-Study
Horm Metab Res 39, 764-768 (2007)
(Fullpaper)

(42) Wilhelm B., Weber M.M., Kreisselmeier H.P., Kugler M., Ries Cl, Pfützner A, Kann H.P., Forst T.
Endothelial Function and Arterial Stiffness in Uncomplicated Typw 1 Diabetes and Healthy Contreols and the Impact of Insulin on These Parameters during an Euglycemic Clamp
J Diab Sci Tech 1 (4), 582-587 (2007)
(Fullpaper)

(43) Pfützner A., Forst F.
Dihydrogenoxid (H20;Wasser)in der klinischen Anwendung am Menschen: Versuch einer theoretischen und praktischen Nutzenevaluierung
Caisson 22. Jg. (3) , 44-46 (2007)
(Fullpaper)

(44) Borchert M., Schöndorf T., Lübben G., Forst T., Pfützner A.
Review of the Pleiatropic Effects of Peroxisome Proliferator-Activated Receptor y Agonists on Platelet Function
Diab Technology & Therapeutics 9 (5), 410-420 (2007)
(Fullpaper)

(45) Kann P.H., Ivan D., Pfützner A., Forst T., Langer P., Schäfer S.
Preoperative diagnosis of insulinoma: low body mass index, young age, and female gender are associated with negative imaging by endoscopic ultrasound
Euro J Endocrin 157, 209-213 (2007)
(Fullpaper)

(46) Hanefeld M., Forst T.
Anti-inflammatory effects of pioglitazone and/or simvastatin in patients with distinct clinical risk for cardiovascular complications
Cardiology 24 (7) , 12-16200 (2007)
(Fullpaper)

(47) Forst T., Smith T., Schütte K., Marcus P., Pfützner A.
Dose Escalating Safety Study of CNS 5161 HCl, a New Neuronal Glutamate Receptor (NMDA) Antagonist for the Treatment of Neuropathic Pain
Brit. J. Clin. Pharmacol. 64, 75 - 82 (2007)
(Fullpaper)

(48) orst T., Pfützner A., Lübben G., Weber M., Marx N., Karagiannis E., Koehler C., Baurecht W., Hohberg C., Hanefeld M.
Effect of Simvastatin and/or Pioglitazone on Insulin Resistance, Insulin Secretion, Adiponectin and Intact Proinsulin Levels in Non-Diabetic Patients at Cardiovascular Risk – The PIOSTAT Study
Metabolism 4, 491-496 (2007)
(Fullpaper)

(49) Pfützner A., Weber M.M., Forst T.
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects
Informa Healthcare, ISSN 1465-6566 (2007)
(Fullpaper)

(50) Schöndorf T., Forst T., Hohberg C., Hoopmann M., Borchert M., Löbig M., Roth W., Grabellus M., Pfützner A.
Relaxin expression correlates significantly with serum fibrinogen increase in response to antidiabetic treatment in postmenopausal women with type 2 diabetes mellitus Gynecol
Endocrinol Clin Lab 3+4, 193-196 (2007)
(Fullpaper)

(51) Pfützner A., Pfützner A.H., Stridde E., Huppertz E., Reimer T., Derwahl M., Forst T., Petrak E.
Insulin Resistance and ß-Cell-Dysfunction in Insufficiently Controlled Type 2 Diabetes
the SETT2D Trial. Diabetes Stoffwechsel und Herz. 2 , 91-97 (2007)
(Fullpaper)

(52) Pfützner A., Forst T.
A Diabetes Outcome and Progression Trial – Die ADOPT-Studie
Der Diabetologe 4, 261-269 (2007)
(Fullpaper)

(53) Hohberg C., Lübben G., Forst T., Gauert S., Karagiannis E, Reimer T., Gottschall V., Pfützner A.
Kardiovaskuläres Risiko bei Diabetes mellitus Typ 2. Diabetes
Stoffwechsel und Herz. 3, 173-177 (2007)
(Fullpaper)

(54) Steiner C., Janez A., Jensterle M., Reisinger K., Forst T., Pfützner A.
Impact of Treatment with Rosiglitazone or Metformin on Biomarkers for Insulin Resistance and Metabolic Syndrome
J Diab Sci Technol 1(2) , 211-217 (2007)
(Fullpaper)

(55) Wilhelm B., Klein J., Friedrich C., Forst S., Pfützner A., Kann P.H., Weber M., Forst T.
Increased Arterial Augmentation and Augmentation Index as Surrogate Paraters for Arteriosclerosis in Subjects with Diabetes Mellitus and Nondiabetic Subjects with Cardiovascular Disease
J of Diab Sci and Technol 1 (2), 260-263 (2007)
(Fullpaper)

(56) Pfützner A., Forst T., März W., Jacob S.
Evidenzbasierte Medizin: Theoretische Grundlagen und aktueller Missbrauch zur Kosteneinsparung im Gesundheitswesen.
Der Internist, Springer Medizin Verlag, 10.1007/s00108-007-1830-0. (2007)
(Fullpaper)

(57) Borchert M., Pfützner A., Breidenbach, M., Forst T., Lübben G., Hohberg C., Armbruster F.P., Schöndorf T.
Die Relaxinexpression korreliert mit Änderungen der Fibrinogenspiegel bei Patientinnen mit Typ 2-Diabetes unter oraler antidiabetischer Therapie
Geburtsh. Frauenheilk 67, 348-351 (2007)
(Fullpaper)

(58) Forst T., Pfützner A
Fixed-dose combination of pioglitazone and glimepiride in the treatment to Type 2 diabetes mellitus
Expert Rev. Endocinol. Metab 2(3), 303-312 (2007)
(Fullpaper)

(59) Hanefeld M., Marx N., Pfuetzner A., Baurecht W., Luebben G., Kargiannis E., Stier U., Forst T.
Anti-Inflammatory Effect of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients with elevated High Sensitive CRP
The PIOSTAT study. J. Am. Coll. Cardiol 3 (49), 290-296 (2007)
(Fullpaper)

(60) Petrak F., Stridde E., Leberkus F., Crispin A., Forst T., Pfützner A.
Development and Validation of a New Measure to Evaluate Psychological Resistance to Insulin Treatment
Diab Care, 2199-2204 (2007)
(Fullpaper)

(61) Eckert S., Erdmann E., Lundershausen R., Forst T., Scherbaum W.A., Schnell O., Standl E., Schumm-Draeger P.-M., Tschöpe D., Walter H., Weber M.
Positionsbstimmung zum Stellenwert von Pioglitazon in der Diabetestherapie.
Dtsch Med Wochenschr 132, 2650-2653 (2007)
(Fullpaper)

(62) Hanefeld M., Marx N., Pfützner A., Baurecht W., Luebben G., Kargiannis E., Stier U., Forst T.
Anti-Inflammatory Effect of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients with elevated High Sensitive CRP: The PIOSTAT study
J. Am. Coll. Cardiol. 49, 291-298 (2007)
(Fullpaper)

(63) Schöndorf T., Forst T., Hohberg C., Pahler S., Link C., Roth W., Pfützner A.
The IRIS III - Study: Pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight
Diab. Obes. Metab. 9, 132-133 (2007)
(Fullpaper)

(64) Mohr T., Pfützner A., Forst S., Forst T., Schöndorf T.
Selfmonitoring of blood glucose levels requires intensive training for use of meters to obtain reliable and clinically relevant measurements
J. Diabetes Sci. Technol. 1, 56-61 (2007)
(Fullpaper)

(65) Pfützner A., Jahn E.
Inhalatives Humaninsulin
Wirkstoffbibliothek 8, 1-32 (2006)
(Fullpaper)

(66) Forst T., Pfützner A.
Kurzwirksame Analoga bei Typ 1 Doabetikern ohne Zusatznutzen?
Diabetes Stoffw. Herz 15(6), 75-83 (2006)
(Fullpaper)

(67) Kerschgens B., Pfützner A., Strotmann H.J., Standl E., Lübben G., Pahler S., Forst T., Schöndorf T.
Adiponectin Values and their correlations to Cardio-Metabolic risk factors
Diabetes Stoffw. Herz 15(6), 9-14 (2006)
(Fullpaper)

(68) Weise A., Lambertz U., Thomé N., Bartz U., Krefft M., Mockenhaupt F., Bienzle U., Schöndorf T., Forst T., Pfützner A.
A fast and reliable single-run method for genotyping of the human cytochrome P450 2C8 gene for different ethnic groups
Clin.Lab. 52, 599-603 (2006)
(Fullpaper)

(69) Lederle M., Pfützner A.
Warum verschreiben Ärzte Insulinanaloga?
Diabetes Stoffw. Herz 15(5), 27-28 (2006)
(Fullpaper)

(70) Forst T., Lübben G., Karagiannis E., Roth W., Pfützner A.
PPARγ Activation Increases Plasma Adiponectin Levels
Diabetes Stoffw. Herz 15(5), 17-19 (2006)
(Fullpaper)

(71) Pfützner A., Forst T.
Comment on: Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909-1914
Diabetologia 49, 2795 (2006)
(Fullpaper)

(72) Pfützner J., Forst T., Butzer R., Forst S., Weber M.M., Pfützner A.H., Pfützner A.
Performance of the Continuous Glucose Monitoring System CGMS during development of Ketosis in Patients on Insulin pump therapy
Diabetic Medicine 23, 1124-1129 (2006)
(Fullpaper)

(73) Hille S., Rein D.T., Riffelmann M., Neumann R., Sartorius J., Pfützner A., Kurbacher C.M., Schondorf T., Breidenbach M.
Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer
Anticancer Drugs (9), 1041-1044 (2006)
(Fullpaper)

(74) Pfützner A., Schneider C., Forst T.
Pioglitazone - Cardioascular aspects of an antidiabetic drug. Exp. Rev.
Cardiovasc. Ther. 4, 445-459 (2006)
(Fullpaper)

(75) Hanefeld M., Pfützner A., Forst T., Lübben G.
Pioglitazone versus Glibenclamide: Significant Differences in Glycemic Control and Treatment Failure Rates in Patients with Type 2 Diabetes Mellitus
Curr Med Res Opin. 22, 1211-1215 (2006)
(Fullpaper)

(76) Pfützner A., Forst T.
Dihydrogenoxid (H2O, Wasser) in der klinischen Anwendung am Menschen - Nutzenevaluierung – Kurzbericht
Diabetes Stoffw. Herz 15(4), 97-98 (2006)
(Fullpaper)

(77) Pfützner A., Forst T.
Evaluation des Kurzberichtes (Rapid Report, V 1.0) des IQWIG zum Thema „Inhalatives Insulin (EXUBERAÒ)“ vom 02.05.2006.
Diabetes Stoffw. Herz 15(4), 97-95 (2006)
(Fullpaper)

(78) Pfützner A., Forst T.
Insulinresistenz und ß-Zelldysfunktion – Epidemio-logische und labormedizinische Charakterisierung von gut und schlecht eingestellten Patienten mit Typ 2 Diabetes unter oraler Therapie in Deutschland
Diabetes Stoffw. Herz 15(Suppl.1), 24-27 (2006)
(Fullpaper)

(79) Pfützner A., Lorra B., Abdollhania M., Kann P.H., Mathieu D., Pehnert C., Oligschleger C., Kaiser M., Forst T.
Preprandial Short-acting Insulin Analogue Substitution has an Immediate and Comprehensive ß-Cell Protective Effect in Patients with Type 2 Diabetes Mellitus - Results from a Randomized Comparator Study vs. Glimepiride
Diab. Technol. Ther. 8, 375-384 (2006)
(Fullpaper)

(80) Wilhelm B., Forst S., Weber M.M., Larbig M., Pfützner A., Forst T.
Evaluation of CGMS((R)) During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes
Diabetes Technol Ther. 8, 146-155 (2006)
(Fullpaper)

(81) Pfützner A., Forst T.
Aktuelle Diabetesforschung in Deutschland.
Diabetesforum 5, 16-20 (2006)
(Fullpaper)

(82) Letzel H., Pfützner A., Forst T.
Insulinanaloga bei Patienten mit Typ 2 Diabetes – Innovation oder Versorgungsirrtum?. Evaluation des IQWiG-Abschlußberichtes zu den kurzwirksamen Insulinanaloga bei Diabetes mellitus Typ 2
Diabetes Stoff. Herz 15(3), 73-80 (2006)
(Fullpaper)

(83) Wilhelm B., Pfützner A., Forst T.
Metabolische Störungen bei kardiovaskulären Risikopatienten
Diabetes Stoffw. Herz 15(3), 59-66 (2006)
(Fullpaper)

(84) Pfützner A., Standl E., Strotmann H.J., Schulze J., Hohberg C., Lübben G., Pahler S., Schöndorf T., Forst T.
Association of hsCRP with Advanced Stage ß-Cell Dysfunction and Insulin Resistance in Patients with Type 2 Diabetes mellitus
Clin. Chem. Lab. Med. 44, 556-560 (2006)
(Fullpaper)

(85) Letzel H., Forst T., Pfützner A.
Mit dem Rücken zur Wand – Prof. Sawicki gerät zunehmend unter Druck
PharmR, 177-182 (2006)
(Fullpaper)

(86) Luft D., Forst T., Pfützner A., Sabatowski R.
Therapie der diabetischen Polyneuropathie
Der Diabetologe 2 , 114-124 (2006)
(Fullpaper)

(87) Forst T, Pfutzner A.
Response to Jean-Luc Cracowski, Gregg R. McCord, Christopher T. Minson. J
Diabetes Complications 20, 134-135 (2006)
(Fullpaper)

(88) Pfützner A., Standl E., Strotmann H.J., Schulze J., Hohberg C., Pahler S., Gottschall V., Lübben G.
IRIS II Study: Epidemiological characteristics of patients with Type 2 diabetes without insulin treatment in Germany
Diabetes Stoffw. Herz 15, 3-10 (2006)
(Fullpaper)

(89) Pfützner A., Forst T.
Pioglitazone – an anti-diabetic drug with the potential to reduce cardiovascular mortality
Exp. Opin. Pharmacother. 7, 463-476 (2006)
(Fullpaper)

(90) Pfützner A., Forst T.
HsCRP as cardiovascular risk marker in patients with diabetes mellitus. Diab.
Technol. Ther. 8, 28-36 (2006)
(Fullpaper)

(91) Kerschgens B., Bartz U., Schulze J., Schöndorf T., Forst T., Pfützner A.
Orphan Drug Gesetzgebung – Auswirkung auf die Zulassung von onkologischen Präparaten in Europa und den USA
DZKF 10, 44-49 (2006)
(Fullpaper)

(92) Kintscher U., Marx N., Koenig W., Pfützner A., Forst T., Schnell O.
Kardiodiabetologie: Der aktuelle Stand – Epidemiologie, Pathophysiologie, Therapie, Klinik und Praxis
Diabetes Stoffwechsel und Herz 15, 31-45 (2006)
(Fullpaper)

(93) Kann P.H., Pfützner A., Delling G., Schulz G., Meyer S.
Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years
Clin Rheumatol. 25, 30-34 (2006)
(Fullpaper)

(94) Pfützner A., Schöndorf T., Seidel D., Winkler K., Matthaei S., Hamann A., Forst T.
Impact of Rosiglitazone on ß-Cell Function, Insulin Resistance and Adiponektin Concentrations – Results from a Double Blind Oral Combination Study with Glimepiride
Metabolism 55, 20-25 (2006)
(Fullpaper)

(95) Forst T., Karagiannis E., Hohberg C., Lübben G., Hanefeld M., Weber M., Pfützner A.
Glucose metabolism and proinsulin intact level during an oral glucose load could be corrected by PPARg-stimulation in non-diabetic patients at risk for cardiovascular disease. 66th Scientific Sessions of the American Diabetes Association, Washington
Diabetes 55(Suppl.1), June 9-13, 2006, A571 (2006)
(Fullpaper)

(96) Wilhelm B., Hanefeld M., Karagiannis E., Lübben G., Weber M.M., Forst T., Pfützner A.
Einfluss einer PPARg-Stimulation auf den postprandialen Glukosemetabolismus und die Proinsulinsekretion der ß-Zelle bei kardiovaskulären Risikopatienten ohne manifesten Diabetes mellitus. 41. Jahrestagung der Deutschen Diabetesgesellschaft
Diabetologie 1(Suppl.1), Leipzig 24.-27. Mai, 2006, S164 (2006)
(Fullpaper)

(97) Pfützner A., Forst T.:
Erfolgreiche kardiovaskuläre Sekundärprävention durch Pioglitazon bei Patienten mit Typ 2 Diabetes – Ergebnisse der PROactive Studie.
Diabetes Stoffw. 15 , 327-331 (2005)
(Fullpaper)

(98) Larbig M., Forst T., Forst S., Lorra B., König K., Fittkau T., Pfützner A.:
Evaluation of the insulin application system Autopen 24. Pract.
Diabetes Int. 22, 364-366 (2005)
(Fullpaper)

(99) Röwer S., Bienzle U., Weise A., Lambertz U., Forst T., Otchwemah R.N., Pfützner A., Mockenhaupt F.P.:
High prevalence of cytochrome P450 2C8*2 mutation in northern Ghana.
Trop. Med. Int. Health 10 , 1271 - 1273 (2005)
(Fullpaper)

(100) Pfützner A., Forst T.:
Pulmonary Insulin Delivery by Means of the Technosphere Drug Carrier System.
Exp. Opin. Drug. Deliv. 2 , 1097-1106 (2005)
(Fullpaper)

(101) Schöndorf T., Maiworm A., Emission N., Forst T., Pfützner A.:
Biological Background and Role of Adiponectin as Marker for Insulin Resistance and Cardiovascular Risk.
Clin Lab. 51 , 489-94 (2005)
(Fullpaper)

(102) Pfützner A., Lübben G., Forst T.:
Pioglitazone Decreases Carotid Intima Media Thickness and other Surrogate Markers of Cardiovascular in Type 2 Diabetes mellitus.
Cardiol. Rev. 22 , 30-34 (2005)
(Fullpaper)

(103) Forst T., Pfützner A.:
Neue pharmakologische Interventionen bei schmerzhafter diabetischer Polyneuropathie.
Diabetes Congress-Report 5 , 42 - 47 (2005)
(Fullpaper)

(104) Forst T., Lübben G., Hohberg C., Kann P., Sachara C., Gottschall V., Friedrich C., Roßkopf R., Pfützner A.:
Influence of Glucose Control and Improvement of Insulin Resistance on Microvascular Blood Flow and Endothelial Function in Patients with Diabetes Mellitus Type 2
Microcirculation 12 , 543-550 (2005)
(Fullpaper)

(105) Forst T., Hohberg C., Fuellert S., Lübben G., Konrad T., Löbig M., Weber M.M., Sachara C., Gottschall V., Pfützner A. :
Pharmacological PPARγ Stimulation in Contrast to Beta Cell Stimulation results in an Improvement in Adiponectin and Proinsulin Intact levels and Reduces Intima Media Thickness in Patients with Type 2 Diabetes.
Horm. Metab. Res. 37 , 521-527 (2005)
(Fullpaper)

(106) Pfützner A., Hohberg C., Lübben G., Pahler S., Pfützner A.H., Kann P., Forst T.:
Pioneer Study: PPARg-Activation Results in an Overall Improvement of Clinical and Metabolic Markers associated with Insulin Resistance independent from Long-Term Glucose Control.
Horm. Metab. Res. 37 , 510-515 (2005)
(Fullpaper)

(107) Pfützner A., Forst T.:
HbA1c : limitations of the Holy Grale in optimised diabetes management and potential value of Continuous Blood Glucose Monitoring?
Infusion Systems 4 , 14 - 16 (2005)
(Fullpaper)

(108) Pfützner A., Marx N., Lübben G. Langenfeld M., Walcher D., Konrad T., Forst T.:
Improvement of Cardiovascular Risk Markers by Pioglitazone is Independent from Glycemic Control - Results from the Pioneer Study. J
Am. Coll. Card. 45, 1925-1931 (2005)
(Fullpaper)

(109) Forst T., Forst S., Strunk C., Löbig M., Welter K., Kazda C., Pfützner A.:
Impact of Insulin on Microvascular Blood Flow and Endothelial Cell Function in the Postprandial State in Type 1 Diabetic Patients
J. Diab. Compl. 19 , 128-132 (2005)
(Fullpaper)

(110) Pfützner A., Standl E., Hohberg C., Konrad T., Strotmann H.J., Lübben G., Pahler S., Langenfeld M., Schulze J., Forst T.:
IRIS II Study: Intact Proinsulin is Confirmed as Highly Specific Marker for Insulin Resistance in a Cross-Sectional Study Design.
Diab. Technol. Ther. 7 , 478-486 (2005)
(Fullpaper)

(111) Pfützner A., Pfützner A.H., Kann P., Stute R., Löbig M., Yang J.W., Mistry J., Forst T.:
Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin.
Clin. Lab. 51 , 734-738 (2005)
(Fullpaper)

(112) Langenfeld M., Forst T., Hohberg C., Kann P., Lübben G., Konrad T., Füllert S., Sachara C., Pfützner A.:
Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with type 2 diabetes mellitus.
Circulation 111 , 2525-2531 (2005)
(Fullpaper)

(113) Hohberg C., Forst T., Pfützner A.:
Adiponektin – Nur ein weiteres Produkt des Fettgewebes?
Diabetes Kongressreport 2 , 14-16 (2005)
(Fullpaper)

(114) Pfützner A., Kerner W.:
Fallstricke in der Diagnostik des Typ 2 Diabetes.
MMW Fortschr. Med. 147, 223-226 (2005)
(Fullpaper)

(115) Forst T., Standl E., Hohberg C., Konrad T., Schulze J., Strotmann H.J., Lübben G., Pahler S., Bachinger A., Langenfeld M., Pfützner A.:
IRIS-II Study: The IRIS-II score – Assessment of a new clinical algorythm for the classification of insulin resistance in patients with type 2 diabetes.
Diabet. Med. 21 , 1149-1153 (2004)
(Fullpaper)

(116) Forst T., Nugyen M., Forst S., Disselhoff B., Pohlmann T., Pfützner A.:
Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes
Nutr. Metab. 17 , 163-168 (2004)
(Fullpaper)

(117) Pfützner A., Caduff A., Larbig M., Schrepfer T., Forst T.:
Impact of Posture and Fixation Technique on Impedance Spectroscopy Used for Continuous and Non-invasive Glucose Monitoring.
Diab. Technol. Ther. 6 , 435-441 (2004)
(Fullpaper)

(118) Pfützner A., Forst T.:
Intaktes Proinsulin als kardiovaskulärer Risikomarker und prädiktiver diagnostischer Marker für die Insulinresistenz bei Patienten mit Typ 2 Diabetes.
Diab. Stoffw. 14 , 193-200 (2004)
(Fullpaper)

(119) Forst T., Larbig M., Pfützner A.:
Blutzucker-Messung beim Diabetiker: Die Tücken der Tests.
Der Allgemeinarzt, 8 , 485-491 (2004)
(Fullpaper)

(120) Pfützner A., Pfützner A.H., Larbig M., Forst T.:
Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus.
Diab. Technol. Ther. 6 , 405-412 (2004)
(Fullpaper)

(121) Pfützner A., Forst T.:
Insulinresistenz und Dysfunktion der Betazellen früher erkennen – Können Typ 2 Diabetiker noch gezielter behandelt werden
MMW Fortschr. Med. 146 , 32-33, 35 (2004)
(Fullpaper)

(122) Weise A., Grundler S., Zaumsegel D., Klotzek M., Forst T., Pfützner A.:
Development and Evaluation of a rapid and reliable method for cytochrom P450 2C8 genotyping,
Clin. Lab. 50 , 141-148 (2004)
(Fullpaper)

(123) Pfützner A., Kunt T., Mondok A., Pahler S., Konrad T., Luebben G., Forst T.:
Fasting Intact Proinsulin is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes.
Diabetes Care 27, 682-687 (2004)
(Fullpaper)

(124) Pfützner A., Forst T.:
Praktische Diagnostik der Insulinresistenz
Diabetes Congress-Report 1 , 16-20 (2004)
(Fullpaper)

(125) Forst T., Pfützner A.:
Risikofaktor für das diabetische Fußsyndrom. Autonome Dysfunktion an der unteren Extremität.
MMW-Forstschr. Med 146 , 33-36 (2004)
(Fullpaper)

(126) Langenfeld M., Forst T., Standl E., Strotmann H.J., Luebben G., Pahler S., Kann P., Pfuetzner A.
IRIS II Study: Sensitivity and Specificity of Intact Proinsulin, Adiponectin and the Proinsulin/Adiponectin Ratio as Markers for Insulin Resistance.
Diab. Technol. Ther. 6 , 836-843 (2004)
(Fullpaper)

(127) Nguyen M., Henniges W., Lobisch M., Reifert S., Larbig M., Pfützner A., Forst T.:
Evaluation of SET – A new device for the measurement of pain perception in comparison to standard measures for diabetic neuropathy.
Diab. Technol. Ther. 6 , 601 - 606 (2004)
(Fullpaper)

(128) Forst T., Pfützner A.:
Die Rolle von C-Peptid bei der Entwicklung mikrozirkulärer diabetischer Folgeerkrankungen.
Diabetes Congress-Report 5 , 10-14 (2004)
(Fullpaper)

(129) Pfützner A., Kann P., Pfützner A.H., Kunt T., Larbig M., Weber M.M., Forst T.:
Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes.
Clin. Lab. 50 , 567-573 (2004)
(Fullpaper)

(130) Tijsse Klasen E., Walrafen D., Spitta L., Schöndorf T., Baumstark-Kahn C., Rettberg P., Pfützner A., Horneck G., Weisshaar M.P.:
The Lux-fluoro assay implies advantageous features for acute toxicity testing.
(Berl). 49(Suppl. 2) , 988-989 (2004)
(Fullpaper)

(131) Weise A., Grundler S., Schöndorf T., Weisshaar M.-P., Forst T., Pfützner A.:
Use of the LightCycler-Method for Genotyping of metabolic enzymes participating in drug-metabolism for Patients with Type 2 Diabetes and Normal Subjects.
Biomed Tech (Berl). 49(Suppl. 2) , 986-987 (2004)
(Fullpaper)

(132) Pfützner A., Caduff A., Forst S., Larbig M., Dewarrat R., Schrepfer T., Weber M.M., Forst T.:
Accuracy of the Non-Invasive Glucose Monitoring Device Pendra® compared to Alternate Site Glucose Measurements at the Lower Forearm during Dynamic Blood Glucose Changes in Type 1 Diabetic Patients.
Biomed Tech (Berl). 49(Suppl. 2) , 984-985 (2004)
(Fullpaper)

(133) Pfützner A., Caduff A., Schrepfer T., Greningloh M., Forst T.:
Stability of Non-invasive Blood Glucose Determinations by Means of the Pendra-Device During Orthostatic Changes of Cutaneous Microcirculation.
(Berl). 49(Suppl. 2) , 980-981 (2004)
(Fullpaper)

(134) Larbig M., Forst T., Mondok A., Forst S., Pfützner A.:
Investigation on the Accuracy of the Blood Glucose Monitoring Device Prestige IQ.
Diab. Nutr. Metab. 16 , 257-261 (2003)
(Fullpaper)

(135) Pfützner A., Langenfeld M., Kunt T., Löbig M., Forst T.:
Evaluation of Human Resistin Assays with Serum from Patients with Type 2 Diabetes and Different Degrees of Insulin Resistance .
Clin. Lab. 49 , 571-576 (2003)
(Fullpaper)

(136) Wallerath T., Kunt T., Forst T., Closs E.I., Lehmann R., Flohr T., Gabriel M., Schäfer D., Gopfert A., Pfützner A., Beyer J., Forstermann U.:
Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide.
Nitric Oxide. 9 , 95-102 (2003)
(Fullpaper)

(137) Pfützner A., Kunt T., Löbig M., Knesovic M., Forst T.:
Clinical and Laboratory Evaluation Characteristics of Two New Chemiluminescence Assays for Intact and Total Proinsulin. Clin
Chem. Lab. Med. 41 , 1234-1238 (2003)
(Fullpaper)

(138) Pfützner A., Flacke F., Pohl R., Linkie D., Engelbach M., Woods R., Forst T., Beyer J., Steiner S.S.:
Technopshere/PTH(1-34) – a new approach for effective pulmonary delivery of parathyroid hormone(1-34).
Horm. Metab. Res. 35, 319-323 (2003)
(Fullpaper)

(139) Pfützner A., Löbig M., Fortunato A., Forst T.:
Evaluation of a new fully automated one-step c-peptide chemiluminescence assay (LIAISON C-Peptid)
Clin. Lab. 49 , 227-232 (2003)
(Fullpaper)

(140) Forst T., Pfützner A.:
Neue Therapieansaätze bei diabetischer peripherer, sensomotorischer Polyneuropathie.
Diabetes Congress-Report , 44-47 (2003)
(Fullpaper)

(141) Forst T., Hohberg C., Pfützner A.:
Nicht-metabolische Effekte einer Therapie mit Thiazolidindionen.
Diabetes Congress-Report (3), 32-35 (2002)
(Fullpaper)

(142) Pfützner A., Mann A.E., Steiner S.S.:
TechnosphereTM/Insulin – A new approach for effective delivery of human insulin via the pulmonary route.
Technol. Ther. 4, 589 – 594 (2002)
(Fullpaper)

(143) Pfützner A., Hermanns N., Schröder S., Wegenstein M., Larbig M., Mondok A., Forst T., Haak T.:
Cross-sectional investigation on the accuracy of alternate site glucose testing using the SoftSense glucose meter.
Cross-sectional investigation on the accuracy of alternate site glucose testing using the SoftSense glucose meter. , 351-357 (2002)
(Fullpaper)

(144) Forst T., Pohlmann T., Kunt T., Goitom K., Schulz G., Löbig M., Engelbach M., Beyer J., Pfützner A.:
The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy.
Acta Diabetol., 39 , 1 – 6 (2002)
(Fullpaper)

(145) Forst T., Rave K., Pfuetzner A., Buchholz R., Pohlmann T., Löbig M., Heinemann L. :
Effect of C-Peptide on Glucose Metabolism in Patients with Type 1 Diabetes.
Diabetes Care, 25 , 1096-1097 (2002)
(Fullpaper)

(146) Forst T., Kunt T., Kazda Ch., Lobisch M., Pfützner A. :
Die Rolle der Proteinkinase C in der Entwicklung mikrovaskulärer Komplikationen des Diabetes mellitus.
Diabetes Stoffw., 11 , 62 – 70 (2002)
(Fullpaper)

(147) Steiner S., Pfützner A., Wilson B.R., Harzer O., Heinemann L., Rave K.:
TechnosphereTM/Insulin – a new insulin formulation for pulmonary delivery Exp. Clin. Endocrinol.
Diab., 110 , 17-21 (2002)
(Fullpaper)

(148) Pfützner A., Forst T.:
Response to Jungheim and Koschinsky (Letter)
Diabetes Care, 25 , 638 – 639 (2002)
(Fullpaper)

(149) Heinemann L., Pfützner A., Heise T.:
Insulin inhalieren statt spritzen!? Inhalatives Insulin als alternative Applikationsform.
Diabetes Stoffw., 10 , 255 – 269 (2001)
(Fullpaper)

(150) Pfützner A., Forst T., Engelbach M., Margin T., Goitom K., Löbig M., Beyer J., Kunt T.:
The influence of isolated small nerve fibre dysfunction on microvascular control in patients with diabetes mellitus
Diabet. Med., 18 , 489 - 494 (2001)
(Fullpaper)

(151) Forst T., Pohlmann T., Goitom K., Beyer J., Kunt T., Pfützner A.:
C-Peptid – Abfallprodukt der Insulinsynthese oder biologisch aktives Protein
Diabetes Stoffw., 10 , 171 -- 179 (2001)
(Fullpaper)

(152) Heinemann L., Pfützner A., Heise T.:
Alternative routes of administration as pulmonary insulin delivery.
Curr. Pharm. Des., 7 , 1327 – 1351 (2001)
(Fullpaper)

(153) Rave K., Heise T., Pfützner A., Heinemann L., Sawicki P.T.:
Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in Type 1 diabetic patients.
Diabetes Care, 24 , 886 – 890 (2001)
(Fullpaper)

(154) Pfützner A., Berger S., Spinas G.A.:
Aktueller Stellenwert der kontinuierlichen subkutanen Insulininfusion (CSII) mit Insulinpumpen in der Therapie des Diabetes mellitus.
Schweiz. Med. Wschr. , 130 , 1954-1961 (2000)
(Fullpaper)

(155) Bruns W., Melchert J., Fischer S., Köhler C., Julius U., Gudat U., Pfützner A., Frank M., Hanefeld M.:
Präprandiale komplementäre Insulintherapie bei übergewichtigem Typ-2-Diabetes – mit Normalinsulin oder schnell wirkendem Insulin-analogon (Lispro-Insulin)?
Diabetes Stoffw., 9 , 219 – 226 (2000)
(Fullpaper)

(156) Herschbach P., Duran G., Attanasio A., Trautmann M.E., Lindner U., Schulze J., Pfützner A.:
Psychische Belastungen bei Diabetes mellitus – Unterschiede zwischen den alten und den neuen Bundesländern 1992 und 1997
Diabetes Stoffw., 9 , 207 – 211 (2000)
(Fullpaper)

(157) Zick R., Schiwietz J., Richter M., Pfützner A.:
Erste klinische Erfahrungen mit einem praxistauglichen Glukosesensor.
Z. Allg. Med., 76 , 255 – 257 (2000)
(Fullpaper)

(158) Engelbach M., Gorges R., Forst T., Pfützner A., Dawood R., Heerdt S., Kunt T., Bockisch A., Beyer J.:
Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements J. Clin. Endocrinol.
Metab., 85 , 1890 - 1894 (2000)
(Fullpaper)

(159) Pfützner A., Harzer O., Kunt T., Forst T., Abdollahnia N., Löbig M., Krauss H., Engelbach M., Kann P., Beyer J.:
Comparison of Immunoassays for the detection of Anti-GAD65 Autoantibodies in Patients with Diabetes Mellitus
Clin. Lab., 46 , 275 – 279 (2000)
(Fullpaper)

(160) Kunt T., Forst T., Schmidt S., Pfützner A., Schneider S., Harzer O., Löbig M., Engelbach M., Goitom K., Pohlmann T., Beyer J.:
Serum levels of substance P are decreased in patients with type 1 diabetes. Exp. Clin. Endocrinol.
Diabetes, 108 , 164 – 167 (2000)
(Fullpaper)

(161) Engelbach M., Kunt T., Kann P., Manfras B., Hankeln T., Forst T., Pfützner A., Heerdt S., Walgenbach S., Lehnert H., Beyer J.:
Prädiktive genetische Untersuchungen – Individualisierung von Diagnostik und Therapie bei Familien mit multipler endokriner Neoplasie Typ II.
Dtsch. Med. Wschr., 125 , 37 – 44 (2000)
(Fullpaper)

(162) Forst T., De La Tour D.D., Kunt T., Pfützner A., Goitom K., Pohlmann T., Schneider S., Johannsson B.L., Wahren J., Löbig M., Engelbach M., Beyer J., Vague P.:
Effects of Proinsulin C-Peptide on Nitric Oxide, Microvascular Blood Flow and Erythrocyte Na+,K+-ATPase Activity in Diabetes Mellitus Type 1
Clin. Sci. (Colch), 98 , 283 -290 (2000)
(Fullpaper)

(163) Frühwald-Schultes B., Kern WE., Beyer J., Forst T., Pfützner A., Peters A.:
Elevated Serum Leptin Concentrations in Type 2 Patients with Microalbuminuria and Macroalbuminuria.
Metabolism, 48 , 1290 - 1293 (1999)
(Fullpaper)

(164) Engelbach M., Forst T., Hankeln T., Tratzky M., Heerdt S., Pfützner A., Kann P., Kunt T., Schneider S., Schmidt E.R., Beyer J.:
Germline Mutations in MEN 1 Gene: Creation of a New Splice Acceptor Site and Insertion of 7 Intron Nucleotides into the mRNA.
Int. J. Mol. Med., 4 , 583 - 485 (1999)
(Fullpaper)

(165) Pfützner A., Lang J.K., Eiermann D.F.:
Assay of free Insulin in Serum of IDDM Patients: Performance of a PEG Precipitation Technique in Conjunction wuth an Ultrasensitive Human Insulin RIA with Regular Human
Carriers. Clin. Lab., 45 , 487 – 492 (1999)
(Fullpaper)

(166) Aisenpreis U., Pfützner A., Giehl M., Keller F., Jehle P.M.:
Pharmacokinetics and Pharmacodynamics of Insulin Lispro Compared with Regular Human Insulin in Haemodialysis Patients with Diabetes mellitus Nephrol. Dial.
Transplant., 14(Suppl. 4) , 5 – 6 (1999)
(Fullpaper)

(167) Kunt T., Forst T., FruhB., Flor T., Schneider S., Harzer O., Pfützner A., Engelbach M., Löbig M., Beyer J.:
Binding of Monocytes from Normolipidemic Hyperglycemic Patients with Type 1 Diabetes to Endothelial Cells is Increased in Vitro. Exp. Clin. Endocrinol.
Diabetes, 107 , 252–256 (1999)
(Fullpaper)

(168) Kunt T., Forst T., Pfützner A., Beyer J., Wahren J.:
The physiological impact of proinsulin C-peptide.
Pathophysiology 5, 257-262 (1999)
(Fullpaper)

(169) Fruehwald-Schultes B., Peters A., Kern W., Beyer J., Pfützner A.:
Serum Leptin is associated with Serum Uric Acid Concentrations in Humans
Metabolism, 48 , 677 – 680 (1999)
(Fullpaper)

(170) Renner R., Pfützner A., Trautmann M.E., Harzer O., Sauter K., Landgraf R.:
Use of Insulin lispro in Continuous Subcutaneous Insulin Infusion Treatment. Results of a Multicenter Trial.
Diabetes Care, 22 , 784 – 788 (1999)
(Fullpaper)

(171) Kunt T., Schneider S., Pfützner A., Goitom K., Engelbach M., Schauf B., Beyer J., Forst T:
: The effect of Human Proinsulin C-Peptide on Erythrocyte Deformability in Patients with Type 1 Diabetes mellitus.
Diabetologia, 42 , 465 – 471 (1999)
(Fullpaper)

(172) Kunt T., Forst T., Wilhelm A., Tritschler H., Pfützner A., Harzer O., Engelbach M., Zschabitz A., Stofft E., Beyer J.:
Alpha-lipoic Acid Reduces Experession of Vascular Cell Adhesion Molecule-1 and Endothelial Adhesion of Human Monocytes after Stimulation with Advanced Glycation End Products Clin.
Sci (Colch), 96 , 75 - 82 (1999)
(Fullpaper)

(173) Forst T., Kunt T., Pohlmann T., Goitom K., Löbig M., Engelbach M., Beyer J., Pfützner A.:
.: Microvaskular Skin Blood Flow Following the Ingestion of 75 g Glucose in Healthy Individuals. Exp.
Clin. Endocrinol. Diabetes, 106 , 454 – 459 (1998)
(Fullpaper)

(174) Kunt T., Forst T., Wilhelm A., Zschabitz A., Gopfert A., Kann P., Pfützner A., Harzer O., Engelbach M., Beyer J., Stofft E.:
Establishment of a Quantitative RT-PCR for Detection of Vascular Cell Adhesion Molecule-1 Transcripts in Endothelial Cells after Stimulation with Advanced Glycation Endproducts. Int.
J. Mol. Med., 2 , 455 - 460 (1998)
(Fullpaper)

(175) Engelbach M., Heerd S., Gorges R., Kunt T., Pfützner A., Forst T., Diefenbach K., Walgenbach S., Beyer J.:
Is there an Ectopic Secretion of Monomeric Calcitonin in the Human Beeing.
Langenbecks Arch Surg., 383 , 456 – 459 (1998)
(Fullpaper)

(176) Forst T., Kunt T., Pfützner A., Beyer J., Wahren J.:
New Aspects on Biological Activity of C-Peptide in IDDM Patients.
Exp. Clin. Endocrinol. Diabetes, 106, 270 - 276 (1998)
(Fullpaper)

(177) Kunt T., Forst T., Harzer O., Buchert G., Pfützner A., Löbig M., Zschabitz A., Stofft E., Engelbach M., Beyer J.
The Influence of Advanced Glycation Endproducts (AGE) on the Expression of Human Endothelial Adhesion Molecules. Exp.
Clin. Endocrinol. Diabetes, 106 , 183 – 188 (1998)
(Fullpaper)

(178) Reichel A., Rietzsch H., Kohler H.J., Pfützner A., Gudat U., Schulze J.
Cessation of Insulin Infusion at Night-Time During CSII-Therapy: Comparison of Regular Human Insulin and Insulin Lispro
Exp. Clin. Endocrinol. Diabetes, 106, 168 - 172 (1998)
(Fullpaper)

(179) Frühwald-Schultes B., Peters A., Kern W., Beyer J., Pfützner A.
Influence of Sex Differences in Subcutaneous Fat Mass on Serum Leptin Concentrations (letter).
Diabetes Care, 21 , 1204 – 1205 (1998)
(Fullpaper)

(180) Forst T., Pfützner A., Kunt T., Pohlmann T., Schenk U., Bauersachs R., Küstner E., Beyer J.
Skin Microcirculation in Patients with Type 1 Diabetes with and without Neuropathy after Neurovascular Stimulation.
Clin. Sci. (Colch), 94, 255 – 261 (1998)
(Fullpaper)

(181) Forst T., Kunt T., Pohlmann T., Goitom K., Engelbach M., Beyer J., Pfützner A.
Biological Activity of C-Peptide on the Skin Microcirculation in Patients with Insulin-Dependent Diabetes Mellitus.
J. Clin. Invest., 101 , 2036 – 2041 (1998)
(Fullpaper)

(182) Piepkorn B., Kann P., Forst T., Andreas J., Pfützner A., Beyer J.
Bone Mineral Density and Bone Metabolism in Diabetes Mellitus.
Horm. Metab. Res., 29, 584 - 591 (1997)
(Fullpaper)

(183) Forst T., Pfützner A., Bauersachs R., Arin M., Bach B., Biehlmaier H., Küstner E., Beyer J.
Comparison of the Microvascular Response to Transcutaneous Electrical Nerve Stimulation and Postocclusive Ichaemia in the Diabetic Foot. J.
Diabetes Complications, 11 , 291 – 297 (1997)
(Fullpaper)

(184) Forst T., Beyer J., Kunt T., Küstner E., Pfützner A.
Die Bedeutung der diabetischen Neuropathie und neurovaskulärer Funktionsstörungen in der Pathogenese trophischer Störungen an der unteren Extremität
Diabetes Stoffw. 6 , 115 - 120 (1997)
(Fullpaper)

(185) Kunt T., Omran W,m Forst T., Engelbach M., Küstner E., Beus J., Böhm A., Gahr S., Pfützner A., Beyer J.
Mediasklerose vom Typ Mönckeberg bei Diabetikern – radiologisches Verteilungsmuster und assoziation mit diabetischen Spätkomplikationen
Diabetes Stoffw., 6 , 102 – 106 (1997)
(Fullpaper)

(186) Stiller R., Gudat U., Pfutzner A., Trautmann M.E., Haslbeck M.
Postprandial Treatment with Insulin Lispro
Diabetes Metab., 23 , 232 – 233 (1997)
(Fullpaper)

(187) Anderson J.H., Brunelle R.L., Koivisto V.A., Pfützner A., Trautmann M.E., Vignati L., DiMarchi R.
Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment
Diabetes, 46 , 265 – 270 (1997)
(Fullpaper)

(188) Pfützner A.
Insulinanaloga
Med. Klinik, 91 , 17 - 18 (1996)
(Fullpaper)

(189) Pfützner A., Küstner E., Forst T., Schulze-Schleppinghoff B., Trautmann M.E., Haslbeck H., Schatz H., Beyer J.
Intensive Insulin Treatment with Insulin Lispro in Patients with Type 1 Diabetes reduces the frequency of hypoglycemic episodes.
Exp. Clin. Endocrinol. Diabetes, 104 , 27 - 32 (1996)
(Fullpaper)

(190) Küstner E., Forst T., Kunt T., Knothe H., Wettich K., Beyer J., Pfützner A.
Leichte und mittelschwere diabetische Fußulcerationen - Therapie mit Loracarbef.
Therapiewoche 26, 1478-1482 (1996)
(Fullpaper)

(191) P. Kann, T. Forst, J. Andreas, A. Pfützner
Diabetes mellitus und Knochenstoffwechsel.
Diabetes und Stoffwechsel , 5: 233-237 (1996)
(Fullpaper)

(192) Forst T., Pfützner A., Ayric H., Ambrosch A., Lehnert H., Küstner E.
Die transkutane elektrische Nervenstimulation in der Therapie der symptomatischen somatosensorischen diabetischen Polyneuropathie.
Diabetes und Stoffwechsel , 5: 203-208 (1996)
(Fullpaper)

(193) Henrichs H.R., Unger H., Trautmann M., Pfützner A.
Severe Insulin Resistence Treated with Insulin Lispro (letter)
Lancet, 348 , 1248 (1996)
(Fullpaper)

(194) Forst T., Pfützner A., .Jahn C., Schmitz H., Lichtwald K., Beyer J., Lehnert H.
Decreaseded Sympatho-Adrenal Activity in Diabetic Patients with Autonomic Dysfunction Following Mental Stress. J. Autonom.
Nerve Syst., 61 , 31 - 36 (1996)
(Fullpaper)

(195) Forst T., Pfützner A., v. Hasselbach Y., Lehnert H., Beyer J.
Evaluation of Neuropathic Involvement by Fibre Type in patients with either insulin- dependent or non-insulin dependent diabetes with and without neurotrophic foot ulceration. Diab.
Nutr. Metabol., 8 , 292 - 297 (1995)
(Fullpaper)

(196) Pfützner A., Forst T., Beyer J.
Immunology of Type 1 Diabetes: The autoimmune destruction of the ß-cell.
The Microbiologist, 6 , 30 - 34 (1995)
(Fullpaper)

(197) Forst T., Pfützner A., Kann P., Schehler B.., Lobmmann R., Schäfer H., Andreas J., Bockisch A., Beyer J.
Peripheral Osteopenia in Adult Patients with Insulin-Dependent Diabetes Mellitus.
Diab. Med., 12 , 874 - 879 (1995)
(Fullpaper)

(198) Pfützner A.
Die Lebensqualität verbessern durch Therapie mit Hydokolloid- verbänden.
Dialog extra, 4 , 36 - 37 (1995)
(Fullpaper)

(199) Horvat S., Varga-Defterdarovic L., Horvat L., Jukic R., Kantoci D., Chung N.N., Schiller P.W., Biesert L., Pfützner A., Rübsamen-Waigmann H.
Synthesis and Bioactivity Studies of 1-Adamantanamine Derivatives of Peptides J. Pept.
Sci., 1 , 303 - 310 (1995)
(Fullpaper)

(200) Ambrosch A., Pfützner A., Ponder B.A.J., Beyer J., Lehnert H.
Multiple endokrine Neoplasie Typ IIa (MEN IIa) - genetisches Screening bei familiärem Tumorsyndrom.
Deut. Med. Wschr., 120 , 615 - 619 (1995)
(Fullpaper)

(201) Forst T., Pfützner A., Kann P., Lobmann R., Schäfer H., Beyer J.
Association between diabetic-autonomic-C-fibre-neuropathy and medial wall calcification and the significance in the outcome of trophic foot lesions Exp. Clin.
Endocrinol., 103 , 94 - 98 (1995)
(Fullpaper)

(202) Pfützner A., Forst Th., Ambrosch A., Schmitz H., Lichtwald K., Beyer J.
Determination of anti GAD65 autoantibodies with ELISA before and after standardization with the International Reference Serum. Exp. Clin. Endocrinol.
Diabetes, 103 , 123 - 125 (1995)
(Fullpaper)

(203) Martin S., Kardorf J., Schulte B., Lampeter E.F., Gries F.A., Melchers I., Wagner R., Bertrams J., Roep B.O., Pfützner A., Pietropaolo M., Kolb H.
Autoantibodies to the Islet Antigen ICA69 Occur in IDDM and in Rheumatoid Arthritis.
Diabetologia, 38 , 351 – 355 (1995)
(Fullpaper)

(204) Forst T., Beyer J., Cordes U., Pfützner A., Küstner E., Moll R., Bockisch A., Lehnert H.
Gynaecomastia in a patient with a ß-HCG producing giant cell carcinoma of the lung.
Exp. Clin. Endocrinol., 103 , 28 - 32 (1995)
(Fullpaper)

(205) Klett G., Pfützner A.
Wirkungsweise von 3-W-Fettsäuren als dietätische Begleittherapie chronischer Erkrankungen.
The Microbiologist, 5 , 13-17 (1994)
(Fullpaper)

(206) Pfützner A.
3-v -Fatty Acids in Patients with Neurodermatitis or Other Inflammatory Skin Diseases - an Old but Effective Therapeutic Approach
The Microbiologist, 5 , 26 (1994)
(Fullpaper)

(207) Pfützner A., Yu S., Rübsamen-Waigmann H.
Antiviral Activity of Peptide T on Different HIV-Strains.
The Microbiologist, 5, 27 - 30 (1994)
(Fullpaper)

(208) Münter K.C., Beyer J., Pfützner A.
Hydrokolloidverbände in der ambulanten Praxis - Klinische und Wirtschaftliche Aspekte.
Kassenarzt, 42 , 44 - 48 (1994)
(Fullpaper)

(209) März W., Schmitz H., Bach G., Kirchgässler K.U., Pfützner A.
Wirksamkeit und Verträglichkeit von mikronisiertem Fenofibrat bei Patienten mit Dyslipidämien.
Münch. Med. Wschr., 136 , 690 - 694 (1994)
(Fullpaper)

(210) Rübsamen-Waigmann H., Maniar J.K., Gerte S., Brede H., Dietrich U., Mahambre G., Pfützner A.
High Proportions of HIV-2 and HIV-1/2 double reactive sera in two Indian states, Maharashtra and Goa: First appearance of an HIV-2 epidemic along with an HIV-1 epidemic outside of Africa.
Zbl. Bakt., 280 , 398 - 402 (1994)
(Fullpaper)

(211) Liedtke S., Adamski M., Geyer R., Pfützner A., Rübsamen-Waigmann H., Geyer H.
Oligosaccharide Profiles of HIV-2 External Envelope Glycoprotein: Dependence on Host Cells and Virus Isolates.
Glycobiology, 4, 477-484 (1994)
(Fullpaper)

(212) Forst T., Kann P., Pfützner A., Lobmann R., Schäfer H., Beyer J.
Association between ”diabetic thick skin syndrome” and neurological disorders in diabetes mellitus.
Acta Diabetol., 31 , 73 - 77 (1994)
(Fullpaper)

(213) Pfützner A., Ambrosch A., Forst T., Beyer J.
Der Einfluß von mikronisiertem Fenofibrat auf kardiovaskuläre Risikofaktoren
Z. Allg. Med., 70 , 510 - 515 (1994)
(Fullpaper)

(214) Haas St., Knauf W., Pfützner A.
Problemwunden - Diabetische Druckulzera, Therapieresistenz mit hydrokolloidem Wundverband überwindbar
Klinikmagazin, 10 (Suppl. II) , 49 - 50 (1994)
(Fullpaper)

(215) Pfützner A., Hampl H., Scholz C., Witteler H., Pfeifer S., Landersz M., Grimm B., Brede H.D., Rübsamen-Waigmann H.
Serological Study of HIV- 1 and HIV-2 Infections in Plasma Samples from the Blood Bank of Abidjan, Ivory Coast.
The Microbiologist, 5 , 5 - 8 (1994)
(Fullpaper)

(216) Pfützner A., Seydlitz F., Ambrosch A., Forst T., Kann P., Schmitz H., Beyer J., Lichtwald K.
Serological Study for the Occurence of Antibodies to Glutamic Acid Decarboxylase (GAD) in Patients with IDDM.
Diab. Nutr. Metabol. 7, 3-9 (1994)
(Fullpaper)

(217) Bohnhorst J., Münter K.C., Pfützner A.
Effektiver Einsatz eines Hydrokolloidverbandes (Algoplaque) zur Therapie des Ulcus cruris venosum - drei Fallbeispiele -
Haut, 5(1) , 12 - 18 (1994)
(Fullpaper)

(218) Forst T., Schmitz H., Pfützner A., Beyer J.
Modifizierter Schweißtest als einfaches Verfahren zur Diagnose der diabetischen C-Faser-Neuropathie
Der Kassenarzt, 34 , 45 - 47 (1994)
(Fullpaper)

(219) Forst Th., Pfützner A., Beyer J., Lobmann R., Schäfer H.
The importance of peripheral autonomic neuropathy in the developement of trophic changes in diabetic feet
Int. Symposium on Diabetic Polyneuropathie, Erlangen, FRG, 5. - 6. März (1993 )
(Fullpaper)

(220) Pfützner A., Forst Th., Kann P., Beyer J.
Diabetes und Führerschein
Versicherungsmedizin, 45 , 149 - 151 (1993)
(Fullpaper)

(221) Kann P., Schulz U., Nink M., Pfützner A., Schrezenmeir J., Beyer J.
Architecture in cortical bone and ultrasound transmission velocity
Clinical Rheumatology, 12, 364 - 367 (1993)
(Fullpaper)

(222) Rübsamen-Waigmann H., Pfützner A., Biesert L.
Wirkung antiviraler Substanzen
Immun. Infekt., 21 , 106 - 110 (1993)
(Fullpaper)

(223) Beyer J., Pfützner A.
Zukunftsperspektiven in der Diabetologie
Akt. Ernähr-Med., 17, 199 - 204 (1992)
(Fullpaper)

(224) Pfützner A., Dietrich U., v. Eichel U., v. Briesen H., Maniar J.K., Brede H.D., Rübsamen-Waigmann H.
HIV-1 and HIV-2 Infections in a High-Risk Population in Bombay, India: Evidence for the Spread of HIV-2 and Presence of a Divergent HIV-1 strain. J.
AIDS, 5 , 972 - 977 (1992)
(Fullpaper)

(225) Pfützner A.
HIV-Infektionen im Säuglings- und Kindesalter.
HIV-Skriptum (Forum Mikrobiologie) , XI/5 - XI/8 (1992)
(Fullpaper)

(226) Pfützner A., März J.
Peptide T - A Review.
The Microbiologist, 3, 8-12 (1992)
(Fullpaper)

(227) Rübsamen-Waigmann H., Pfützner A., Scholz C., Maniar J.K., Brede H.D.
HIV-1 and HIV-2 Infections among Urban High Risk Group in India. AIDS Res.
Hum. Retrovir., 5 , 933 (1992)
(Fullpaper)

(228) Pfützner A.
Effect of physiological peptide T on HIV replication
Wiss. Zeitschrift der Humboldt-Univ. Berlin, R. Medizin, 40 (4) , 72 - 74 (1991)
(Fullpaper)

(229) Pfützner A., Rübsamen-Waigmann H.
Cellular Modification of Proteins - N- terminal Myristoylation
The Microbiologist, 2 (3) , 127 - 130 (1991)
(Fullpaper)

(230) Pfützner A., Kunz H.
Synthesis of glycopeptides
The Microbiologist, 2 (3) , 122 - 126 (1991)
(Fullpaper)

(231) Pfützner A., Rübsamen-Waigmann H.
Peptid T in der AIDS Therapie HIV-Skriptum
(Forum Mikrobiologie) , X/13 - X/14 (1991)
(Fullpaper)

(232) Horvat S., Varga L., Horvat J., Pfützner A., Suhartono H., Rübsamen- Waigmann H.
[Leu5]enkephalin related glyco-conjugates - A novel agents effective against HIV-1. Helv
Chim. Acta, 74 , 951 - 955 (1991)
(Fullpaper)

(233) Rübsamen-Waigmann H., v. Briesen H., Maniar J.K., Rao A., Scholz C., Pfützner A.
Spread of HIV-2 in India
Lancet, 337 , 550 - 551 (1991)
(Fullpaper)

(234) Rübsamen-Waigmann H., Pfützner A., Schäfer V.
Antivirale Chemo- therapie gegen den AIDS Erreger HIV
Nachr. Chem. Lab. Tech., 39 , 193 - 195 (1991)
(Fullpaper)

(235) Goetzens M., Pfützner A., Rübsamen-Waigmann H., Brede H.D.
Detection of HIV-antibodies in saliva
The Microbiologist, 1 (2) , 87 - 89 (1990)
(Fullpaper)

(236) Goetzens M., Pfützner A., Rübsamen-Waigmann H., Brede H.D
Nachweis von HIV-Antikörpern im Speichel. HIV-Skriptum (Forum Mikrobiologie)
GIT Verlag, V16 - V18 (1990)
(Fullpaper)

(237) Pfützner A, Rübsamen-Waigmann H.:
Inhibition der HIV-Protease - Eine neue Front gegen AIDS. HIV-Scriptum (Forum Mikrobiologie),
GIT Verlag , X8 - X9 (1989)
(Fullpaper)

(238) Edenharder R., Pfützner A., Hammann R
Characterization of NAD-depen-dent 3a- and 3ß-hydroxysteroid dehydrogenase and of NADP- dependent 7ß-hydroxysteroid dehydrogenase from Peptostreptococcus pro-ductus. Biochim
Biophys. Acta, 1004 , 230 - 238 (1989)
(Fullpaper)

(239) Edenharder R., Pfützner A
Characterization of NADP-dependent 12ß- hydroxysteroid dehydrogenase from Clostridium paraputrificum
Biophys. Acta, 962 , 362-370 (1988)
(Fullpaper)

(240) Hohberg C., Pfützner A., Forst T., Lübben G., Karagiannis E., Borchert M. Schöndorf T.
atmentSuccessful switch from insulin therapy to tre with pioglitazone in type 2 diabetes patients with residual ß-cell function: results from the PioSwitch Study.
Diabetes, Obesity and Metabolism, 464-471 (11/2009)
(Fullpaper)

(241) Forst T., Hohberg C., Schöndorf T., Borchert M., Forst S., Roth W., Dehos B., Pfützner A.
Time-Action Profile and Patient Assessment of Inhaled Insulin via the Exhubera Device in Comparison with Subcutaneously Injected Insulin Aspart via the FlexPen Device.
Diab Techn and Therap, 11 (2) 87-92 (-)
(Fullpaper)